qed THERAPEUTICS
QED Therapeutics is dedicated to developing meaningful treatment options for those with skeletal dysplasias, including achondroplasia and hypochondroplasia. They focus on research and clinical trials to better understand these conditions and evaluate investigational therapies, such as infigratinib, to address the root causes of abnormal bone growth.
Industries
Nr. of Employees
small (1-50)
qed THERAPEUTICS
3160 Porter Drive, Suite 250, Palo Alto, CA, 94304
Products
Clinical trial documentation and scientific posters
Downloadable scientific posters and study-design documents summarizing preclinical activity, trial designs, baseline characteristics, and quality-of-life research related to skeletal dysplasia programs.
Clinical trial documentation and scientific posters
Downloadable scientific posters and study-design documents summarizing preclinical activity, trial designs, baseline characteristics, and quality-of-life research related to skeletal dysplasia programs.
Services
Multi-phase clinical research program including an observational natural-history study and interventional Phase 2/Phase 3 trials evaluating an oral FGFR-targeted investigational therapy in children and adolescents with achondroplasia, with options for open-label extension.
Observational and subsequent interventional study program to characterize hypochondroplasia natural history and evaluate an oral FGFR-targeted investigational therapy in children and adolescents, including eligibility criteria requiring genetic confirmation.
Preclinical testing of FGFR-selective small molecules in animal models to assess activity, dosing strategies, and therapeutic rationale for clinical translation.
Multi-phase clinical research program including an observational natural-history study and interventional Phase 2/Phase 3 trials evaluating an oral FGFR-targeted investigational therapy in children and adolescents with achondroplasia, with options for open-label extension.
Observational and subsequent interventional study program to characterize hypochondroplasia natural history and evaluate an oral FGFR-targeted investigational therapy in children and adolescents, including eligibility criteria requiring genetic confirmation.
Preclinical testing of FGFR-selective small molecules in animal models to assess activity, dosing strategies, and therapeutic rationale for clinical translation.
Expertise Areas
- Clinical trial management
- Natural history studies in rare pediatric skeletal dysplasias
- Preclinical pharmacology and animal models
- FGFR-targeted small-molecule development
Key Technologies
- FGFR-selective tyrosine kinase inhibitors
- Murine preclinical models
- Randomized double-blind placebo-controlled trial design
- Observational natural history study design
News & Updates
Infigratinib is the first investigational therapy for achondroplasia to receive breakthrough therapy designation by the FDA.
Infigratinib is the first investigational therapy for achondroplasia to receive breakthrough therapy designation by the FDA.